4-(2-氰基苯基)哌嗪-1-羧酸叔丁酯 | 179250-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(2-氰基苯基)哌嗪-1-羧酸叔丁酯
• 中文别名: 1-BOC-4-(2-氰基苯基)哌嗪
• 英文名称: tert-butyl 4-(2-cyanophenyl)piperazine-1-carboxylate
• CAS: 179250-25-0
• 化学式: C₁₆H₂₁N₃O₂
• mdl: MFCD08275016
• 分子量: 287.362
• InChiKey: OLDBLJCXZXMUEO-UHFFFAOYSA-N

物化性质

• 沸点：
  435.6±40.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-4-(2-cyanophenyl)piperazine
Synonyms: tert-Butyl 4-(2-cyanophenyl)piperazine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-4-(2-cyanophenyl)piperazine
CAS number: 179250-25-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H21N3O2
Molecular weight: 287.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-氰基苯基)哌嗪-1-羧酸叔丁酯 在 氧化铂 氢气 、 乙醇 、 溶剂黄146 、 氧化铂 、 水 、 乙醚 、 magnesium sulfate 作用下， 以 acetic acid ethanol 为溶剂， 反应 38.0h， 以to give the crude title compound as a pale yellow oil (2.03 g, 100%), δH (360 MHz, CDCl3) 7.34-7.08 (4H, m), 3.91 (2H, s), 3.57 (4H, t, J 4.9 Hz), 2.87 (4H, t, J 4.9 Hz), 1.60 (2H, br s), and 1.49 (9H, s)的产率得到4-(2-(氨基甲基)苯基)哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  Serine derivatives and their use as therapeutic agents

  摘要：

  本发明涉及式（I）的化合物：##STR1## 其中，m为零，1或2；n为零或1，但须满足m+n的总和为1或2；R.sup.1代表苯基；萘基；苯基甲基；或苄基，其中萘基或任何苯基基团可以被取代；R.sup.2代表氢；苯基；从吲唑基、噻吩基、呋喃基、吡啶基、噻唑基、四唑基和喹啉基中选择的杂环基；萘基；苯基甲基；或苄基；其中每个杂环基、萘基和任何苯基基团可以被取代；R.sup.3和R.sup.4各自独立地代表氢或C.sub.1-6烷基，或者R.sup.3和R.sup.4一起连接形成C.sub.1-3烷基链；Q代表CR.sup.5R.sup.6或NR.sup.5；X和Y各自独立地代表氢，或者一起形成.dbd.O基团；Z代表键，O，S，SO，SO.sub.2，NR.sup.c或--(CR.sup.cR.sup.d)--，其中R.sup.c和R.sup.d各自独立地代表氢或C.sub.1-6烷基；或其药学上可接受的盐。这些化合物特别适用于治疗或预防疼痛、炎症、偏头痛、恶心和带状疱疹后神经痛。

  公开号：

  US05885999A1
• 作为产物：
  描述：

  2-氟苯腈 在 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 为溶剂， 反应 18.0h， 生成 4-(2-氰基苯基)哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  [FR] INHIBITEURS DE KINASE CYCLINE-DÉPENDANTE 7 (CDK7)

  摘要：

  本发明提供了如下所述的新化合物，例如式（I）的化合物，以及其药学上可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物和其组合物。还提供了涉及这些化合物或组合物用于治疗或预防增生性疾病（例如癌症（例如白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增生性疾病的受试者可能抑制细胞周期依赖性激酶7（CDK7）的异常活性，从而诱导细胞凋亡和/或抑制受试者的转录。

  公开号：

  WO2015154022A1

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Site-Selective Copper-Catalyzed Amination and Azidation of Arenes and Heteroarenes via Deprotonative Zincation
  作者：Charles E. Hendrick、Katie J. Bitting、Seoyoung Cho、Qiu Wang

  DOI：10.1021/jacs.7b07661

  日期：2017.8.23

  effective for a wide range of arenes, including nonactivated arenes bearing simple functionalities such as fluoride, chloride, ester, amide, ether, nitrile, and trifluoromethyl groups as well as heteroarenes including indole, thiophene, pyridine, and isoquinoline. An analogous C-H azidation is also accomplished using azidoiodinane for direct introduction of a useful azide group onto a broad scope of arenes

  芳烃胺化是通过位点选择性 CH 锌化，然后在温和条件下铜催化与 O-苯甲酰羟胺偶联来实现的。这一成功的关键是由氨基二乙基锌酸锂介导的邻位锌化，它对多种芳烃有效，包括带有简单官能团的非活化芳烃，如氟化物、氯化物、酯、酰胺、醚、腈和三氟甲基以及杂芳烃包括吲哚、噻吩、吡啶和异喹啉。类似的 CH 叠氮化也可以使用叠氮碘来完成，将有用的叠氮基团直接引入到广泛的芳烃和杂芳烃上。这些新的转化提供了快速获得有价值且多样化的氨基芳烃化学空间的途径。通过后期胺化和叠氮化反应合成天然产物 (-)-尼古丁和抗抑郁药舍曲林的新型类似物，证明了它们在有机合成和药物发现中的广泛应用。
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• Identification of novel GLUT inhibitors
  作者：Holger Siebeneicher、Marcus Bauser、Bernd Buchmann、Iring Heisler、Thomas Müller、Roland Neuhaus、Hartmut Rehwinkel、Joachim Telser、Ludwig Zorn

  DOI：10.1016/j.bmcl.2016.02.050

  日期：2016.4

  The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against

  使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1（GLUT1）的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究（SAR），揭示了必要的结构动机（即，邻甲氧基取代的苯，哌嗪和嘧啶）。对GLUT2的选择性非常好，并且最初的体外和体内药代动力学（PK）研究令人鼓舞。
• [EN] TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2017058716A1

  公开（公告）日：2017-04-06

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.

  本文提供了包含所述化合物的药物组合物，用于治疗癌症或先天性疾病。具体的癌症和先天性疾病包括那些由YAP/TAZ介导的疾病。